International Journal of Endocrinology and Metabolism

Published by: Kowsar

Macrocytic Anemia and Thrombocytopenia Induced by Orlistat

David Palacios-Martinez 1 , * , Juan Carlos Garcia-Alvarez 2 , Nieves Montero-Santamaria 1 , Olga Patricia Villar-Ruiz 3 , Antonio Ruiz-Garcia 4 and Raquel Asuncion Diaz-Alonso 1
Authors Information
1 San Blas Health Center, Primary Health Care, SERMAS- Madrid Health Service, Parla, Madrid, Spain
2 Local Office of Serranillos del Valle, Primary Health Care, SERMAS- Madrid Health Service, Griñón, Madrid, Spain
3 Service of Obstetrics and Gynecology, 12th October Universitary Hospital , SERMAS- Madrid Health Service, Madrid, Spain
4 Pinto Health Center, Primary Health Care: SERMAS- Madrid Health Service, Pinto, Madrid, Spain
Article information
  • International Journal of Endocrinology and Metabolism: September 01, 2013, 11 (4); e6721
  • Published Online: October 1, 2013
  • Article Type: Case Report
  • Received: October 17, 2012
  • Revised: February 26, 2013
  • Accepted: April 13, 2013
  • DOI: 10.5812/ijem.6721

To Cite: Palacios-Martinez D, Garcia-Alvarez J C, Montero-Santamaria N, Villar-Ruiz O P, Ruiz-Garcia A, et al. Macrocytic Anemia and Thrombocytopenia Induced by Orlistat, Int J Endocrinol Metab. 2013 ;11(4):e6721. doi: 10.5812/ijem.6721.

Abstract
Copyright: Copyright © 2013, International Journal of Endocrinology and Metabolism. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Case Report
3. Evolution
4. Discussion
Acknowledgements
Footnotes
References
  • 1. Dyson PA. The therapeutics of lifestyle management on obesity. Diabetes Obes Metab. 2010; 12(11): 941-6[DOI][PubMed]
  • 2. Kang JG, Park CY. Anti-Obesity Drugs: A Review about Their Effects and Safety. Diabetes Metab J. 2012; 36(1): 13-25[DOI][PubMed]
  • 3. Carrasco NF, Manrique M, de la Maza MP, Moreno M, Albala C, Garcia J, et al. [Statement about the medical and surgical treatment of overweight and obesity]. Rev Med Chil. 2009; 137(7): 972-81[PubMed]
  • 4. Ballinger Anne, Peikin Steven R. Orlistat: its current status as an anti-obesity drug. Eur J Pharmacol. 2002; 440(2-3): 109-117[DOI]
  • 5. Bloch Katia Vergetti, Salles Gil Fernando, Muxfeldt Elizabeth Silaid, da Rocha Nogueira Armando. Orlistat in hypertensive overweight/obese patients. J Hypertens. 2003; 21(11): 2159-2165[DOI]
  • 6. MacWalter RS, Fraser HW, Armstrong KM. Orlistat enhances warfarin effect. Ann Pharmacother. 2003; 37(4): 510-2[PubMed]
  • 7. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf. 2008; 31(1): 53-65[PubMed]
  • 8. Ahmad FA, Mahmud S. Acute pancreatitis following orlistat therapy: report of two cases. JOP. 2010; 11(1): 61-3[PubMed]
  • 9. García Aguilera Xavier, Teruel Sánchez-Vegazo Carlos, Crespo Pérez Laura, Moreira Vicente Víctor. Pancreatitis aguda inducida por orlistat. Medicina Clínica. 2008; 130(14): 557[DOI]
  • 10. Karamadoukis L, Shivashankar GH, Ludeman L, Williams AJ. An unusual complication of treatment with orlistat. Clin Nephrol. 2009; 71(4): 430-2[PubMed]
  • 11. Kim DH, Lee EH, Hwang JC, Jeung JH, Kim do H, Cheong JY, et al. [A case of acute cholestatic hepatitis associated with Orlistat]. Taehan Kan Hakhoe Chi. 2002; 8(3): 317-20[PubMed]
  • 12. Lau G, Chan CL. Massive hepatocellular [correction of hepatocullular] necrosis: was it caused by Orlistat? Med Sci Law. 2002; 42(4): 309-12[PubMed]
  • 13. Ringman JM, Mozaffar T. Myopathy associated with chronic orlistat consumption: a case report. Neuromuscul Disord. 2008; 18(5): 410-2[DOI][PubMed]
  • 14. Perdue BE, Standiford HC, Yu VL, Merigan TC, Barriere SL. Tetracyclines. In: Antimicrobial Therapy and Vaccines. 1998;
  • 15. Hoffbrand V, Provan D. ABC of clinical haematology. Macrocytic anaemias. BMJ. 1997; 314(7078): 430-3[PubMed]
  • 16. Savage David, Lindenbaum John. Anemia in Alcoholics. Medicine. 1986; 65(5): 322-338[DOI]
  • 17. Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med. 2007; 357(6): 580-7[DOI][PubMed]
  • 18. Christie DJ, Mullen PC, Aster RH. Fab-mediated binding of drug-dependent antibodies to platelets in quinidine- and quinine-induced thrombocytopenia. J Clin Invest. 1985; 75(1): 310-4[DOI][PubMed]
  • 19. Greinacher A, Fuerll B, Zinke H, Mullejans B, Kruger W, Michetti N, et al. Megakaryocyte impairment by eptifibatide-induced antibodies causes prolonged thrombocytopenia. Blood. 2009; 114(6): 1250-3[DOI][PubMed]
  • 20. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30(2): 239-45[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader